TCN-201 | CAS#852918-02-6 | NMDA Antagonist

MedKoo Cat#: 530663 | Name: TCN-201

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TCN-201 is a selective antagonist of NMDA receptors containing the NR2A subunit. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner.

Chemical Structure

TCN-201

CAS#852918-02-6

Theoretical Analysis

MedKoo Cat#: 530663

Name: TCN-201

CAS#: 852918-02-6

Chemical Formula: C21H17ClFN3O4S

Exact Mass: 461.0612

Molecular Weight: 461.89

Elemental Analysis: C, 54.61; H, 3.71; Cl, 7.67; F, 4.11; N, 9.10; O, 13.86; S, 6.94

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 450.00	2 Weeks
10mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

TCN-201, TCN 201, TCN201

IUPAC/Chemical Name

4-[[[(3-chloro-4-fluorophenyl)sulfonyl]amino]methyl]-benzoic acid 2-benzoylhydrazide

InChi Key

FYIBXBFDXNPBSF-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H17ClFN3O4S/c22-18-12-17(10-11-19(18)23)31(29,30)24-13-14-6-8-16(9-7-14)21(28)26-25-20(27)15-4-2-1-3-5-15/h1-12,24H,13H2,(H,25,27)(H,26,28)

SMILES Code

O=C(NNC(C1=CC=CC=C1)=O)C2=CC=C(CNS(=O)(C3=CC=C(F)C(Cl)=C3)=O)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 461.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lotti JS, Jones J, Farnsworth JC, Yi F, Zhao F, Menniti FS, Volkmann RA, Clausen RP, Hansen KB. Evaluation of allosteric NMDA receptor modulation by GluN2A-selective antagonists using pharmacological equilibrium modeling. Mol Pharmacol. 2024 Nov 5:MOLPHARM-AR-2024-000975. doi: 10.1124/molpharm.124.000975. Epub ahead of print. PMID: 39500597. 2: Cavalcante DP, Nunes AÍDS, da Silva ER, de Carvalho GA, Chiareli RA, Oliveira-Lima OC, Ortiz-Leoncini G, Ulrich H, Gomez RS, Pinto MCX. GlyT1 inhibition promotes neuroprotection in the middle cerebral artery occlusion model through the activation of GluN2A-containing NMDAR. Exp Neurol. 2024 Oct 17;383:115006. doi: 10.1016/j.expneurol.2024.115006. Epub ahead of print. PMID: 39424040. 3: Steigerwald R, Chou TH, Furukawa H, Wünsch B. GluN2A-Selective NMDA Receptor Antagonists: Mimicking the U-Shaped Bioactive Conformation of TCN-201 by a [2.2]Paracyclophane System. ChemMedChem. 2022 Nov 4;17(21):e202200484. doi: 10.1002/cmdc.202200484. Epub 2022 Oct 13. PMID: 36169098; PMCID: PMC9828697. 4: Elmasri M, Lotti JS, Aziz W, Steele OG, Karachaliou E, Sakimura K, Hansen KB, Penn AC. Synaptic Dysfunction by Mutations in GRIN2B: Influence of Triheteromeric NMDA Receptors on Gain-of-Function and Loss-of-Function Mutant Classification. Brain Sci. 2022 Jun 15;12(6):789. doi: 10.3390/brainsci12060789. PMID: 35741674; PMCID: PMC9221112. 5: Nuno-Perez A, Mondoloni S, Tchenio A, Lecca S, Mameli M. Biophysical and synaptic properties of NMDA receptors in the lateral habenula. Neuropharmacology. 2021 Sep 15;196:108718. doi: 10.1016/j.neuropharm.2021.108718. Epub 2021 Jul 14. PMID: 34273390. 6: Rajan R, Schepmann D, Steigerwald R, Schreiber JA, El-Awaad E, Jose J, Seebohm G, Wünsch B. [2.2]Paracyclophane-Based TCN-201 Analogs as GluN2A-Selective NMDA Receptor Antagonists. ChemMedChem. 2021 Oct 15;16(20):3201-3209. doi: 10.1002/cmdc.202100400. Epub 2021 Aug 3. PMID: 34265163; PMCID: PMC8596836. 7: Singla R, Mishra A, Joshi R, Kumar R, Sarma P, Sharma AR, Kaur G, Bhatia A, Medhi B. Inhibition of the ERK1/2 Phosphorylation by Dextromethorphan Protects against Core Autistic Symptoms in VPA Induced Autistic Rats: In Silico and in Vivo Drug Repurposition Study. ACS Chem Neurosci. 2021 May 19;12(10):1749-1767. doi: 10.1021/acschemneuro.0c00672. Epub 2021 Apr 29. PMID: 33913688. 8: Troyner F, Bertoglio LJ. Nucleus reuniens of the thalamus controls fear memory reconsolidation. Neurobiol Learn Mem. 2021 Jan;177:107343. doi: 10.1016/j.nlm.2020.107343. Epub 2020 Nov 23. PMID: 33242589. 9: Rajan R, Schepmann D, Schreiber JA, Seebohm G, Wünsch B. Synthesis of GluN2A-selective NMDA receptor antagonists with an electron-rich aromatic B-ring. Eur J Med Chem. 2021 Jan 1;209:112939. doi: 10.1016/j.ejmech.2020.112939. Epub 2020 Oct 15. PMID: 33162207. 10: Li YH, Li Y, Zheng L, Wang J. Postsynaptic GluN2B-containing NMDA receptors contribute to long-term depression induction in medial vestibular nucleus neurons of juvenile rats. Neurosci Lett. 2020 Jan 10;715:134674. doi: 10.1016/j.neulet.2019.134674. Epub 2019 Dec 3. PMID: 31809803. 11: Summer SL, Kell SA, Zhu Z, Moore R, Liotta DC, Myers SJ, Koszalka GW, Traynelis SF, Menaldino DS. Di-aryl Sulfonamide Motif Adds π-Stacking Bulk in Negative Allosteric Modulators of the NMDA Receptor. ACS Med Chem Lett. 2019 Jan 4;10(3):248-254. doi: 10.1021/acsmedchemlett.8b00395. PMID: 30891121; PMCID: PMC6421532. 12: Vijayakumar S, Manogar P, Prabhu S, Pugazhenthi M, Praseetha PK. A pharmacoinformatic approach on Cannabinoid receptor 2 (CB2) and different small molecules: Homology modelling, molecular docking, MD simulations, drug designing and ADME analysis. Comput Biol Chem. 2019 Feb;78:95-107. doi: 10.1016/j.compbiolchem.2018.11.013. Epub 2018 Nov 22. PMID: 30500557. 13: Schreiber JA, Müller SL, Westphälinger SE, Schepmann D, Strutz-Seebohm N, Seebohm G, Wünsch B. Systematic variation of the benzoylhydrazine moiety of the GluN2A selective NMDA receptor antagonist TCN-201. Eur J Med Chem. 2018 Oct 5;158:259-269. doi: 10.1016/j.ejmech.2018.09.006. Epub 2018 Sep 6. PMID: 30218911. 14: Punnakkal P, Dominic D. NMDA Receptor GluN2 Subtypes Control Epileptiform Events in the Hippocampus. Neuromolecular Med. 2018 Mar;20(1):90-96. doi: 10.1007/s12017-018-8477-y. Epub 2018 Jan 15. PMID: 29335819. 15: Müller SL, Schreiber JA, Schepmann D, Strutz-Seebohm N, Seebohm G, Wünsch B. Systematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201. Eur J Med Chem. 2017 Mar 31;129:124-134. doi: 10.1016/j.ejmech.2017.02.018. Epub 2017 Feb 14. PMID: 28222314. 16: Hackos DH, Hanson JE. Diverse modes of NMDA receptor positive allosteric modulation: Mechanisms and consequences. Neuropharmacology. 2017 Jan;112(Pt A):34-45. doi: 10.1016/j.neuropharm.2016.07.037. Epub 2016 Jul 30. PMID: 27484578. 17: Go BS, Barry SM, McGinty JF. Glutamatergic neurotransmission in the prefrontal cortex mediates the suppressive effect of intra-prelimbic cortical infusion of BDNF on cocaine-seeking. Eur Neuropsychopharmacol. 2016 Dec;26(12):1989-1999. doi: 10.1016/j.euroneuro.2016.10.002. Epub 2016 Oct 17. PMID: 27765467; PMCID: PMC5136511. 18: Yi F, Mou TC, Dorsett KN, Volkmann RA, Menniti FS, Sprang SR, Hansen KB. Structural Basis for Negative Allosteric Modulation of GluN2A-Containing NMDA Receptors. Neuron. 2016 Sep 21;91(6):1316-1329. doi: 10.1016/j.neuron.2016.08.014. Epub 2016 Sep 8. PMID: 27618671; PMCID: PMC5033714. 19: Bu F, Du R, Li Y, Quinn JP, Wang M. NR2A contributes to genesis and propagation of cortical spreading depression in rats. Sci Rep. 2016 Mar 22;6:23576. doi: 10.1038/srep23576. PMID: 27001011; PMCID: PMC4802317. 20: Cheriyan J, Balsara RD, Hansen KB, Castellino FJ. Pharmacology of triheteromeric N-Methyl-D-Aspartate Receptors. Neurosci Lett. 2016 Mar 23;617:240-6. doi: 10.1016/j.neulet.2016.02.032. Epub 2016 Feb 23. PMID: 26917100; PMCID: PMC5312704.